Pharmacological inhibition of the kinase activity of AXL has been demonstrated to counteract drug resistance in tyrosine kinase inhibitors (TKIs) in vitro and in vivo, which is an approach that is currently being tested in clinical trials for several types of cancers (9). Here, AXL is linked to cancer.